1403574-71-9

Upstream product

• 1403567-97-4 C₁₂H₁₆N₆O₅ 
• 170112-37-5 C₂₄H₄₁N₃O₆Si₂ 
• 1403249-53-5 C₂₄H₄₂N₆O₆Si₂ 
• 1256490-52-4 (S)-2-[(2,3,4,5,6-pentafluorophenoxy)phenoxyphosphorylamino]propionic acid isopropyl ester 
• 1403249-54-6 C₁₀H₁₄N₆O₄ 
• 261909-49-3 phenyl(isopropoxy-L-alaninyl) phosphorochloridate 
• 65-46-3 CYTIDINE 
• 69304-42-3 3',5'-O-[(1,1,3,3-tetraisopropyl)-1,3-disiloxanediyl]cytidine 
• 85335-73-5 N₄-acetyl-3',5'-O-(tetraisopropyldisiloxane-1,3-diyl)cytidine 
• 140859-16-1 N⁴-acetyl-1-<3,5-O-(tetraisopropyldisiloxane-1,3-diyl)-β-D-erythro-pentofuran-2-ulosyl>cytosine 

Downstream Products

• 1605283-86-0 C₂₆H₃₆N₇O₉P 
• 1605283-89-3 C₃₀H₄₂N₇O₁₀P 
• 1605283-90-6 C₂₆H₃₆N₇O₉P 

Relevant academic research and scientific papers

2'-AZIDO SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to 2′-Azido Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein B, X, R1, R2 and R3 are as defined herein. The present invention also relates to compositions comprising at least one 2′-Azido Substituted Nucleoside Derivative, and methods of using the 2′-Azido Substituted Nucleoside Derivatives for treating or preventing HCV infection in a patient.

2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to 2'-Methyl Substituted Nucleoside Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3, are as defined herein. The present invention also relat